ORIC PHARMACEUTICALS INC's ticker is ORIC and the CUSIP is 68622P109. A total of 93 filers reported holding ORIC PHARMACEUTICALS INC in Q4 2023. The put-call ratio across all filers is 0.86 and the average weighting 0.6%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $35,371 | +243.0% | 5,003 | +567.1% | 0.00% | – |
Q1 2024 | $10,312 | -87.9% | 750 | -91.9% | 0.00% | -100.0% |
Q4 2023 | $85,146 | +81.9% | 9,255 | +19.6% | 0.00% | 0.0% |
Q3 2023 | $46,814 | +186.9% | 7,738 | +268.0% | 0.00% | 0.0% |
Q2 2023 | $16,319 | +30690.6% | 2,103 | -76.8% | 0.00% | -50.0% |
Q4 2022 | $53 | -99.8% | 9,077 | +30.3% | 0.00% | – |
Q3 2022 | $22,000 | -60.0% | 6,967 | -42.4% | 0.00% | -100.0% |
Q2 2022 | $55,000 | -41.5% | 12,093 | -31.0% | 0.00% | 0.0% |
Q1 2022 | $94,000 | +683.3% | 17,530 | +2056.2% | 0.00% | – |
Q4 2021 | $12,000 | -77.4% | 813 | -67.6% | 0.00% | -100.0% |
Q3 2021 | $53,000 | +65.6% | 2,510 | +34.7% | 0.00% | 0.0% |
Q2 2021 | $32,000 | -15.8% | 1,863 | +20.0% | 0.00% | 0.0% |
Q1 2021 | $38,000 | -57.3% | 1,552 | -41.1% | 0.00% | -66.7% |
Q4 2020 | $89,000 | -53.9% | 2,635 | -65.9% | 0.00% | +50.0% |
Q3 2020 | $193,000 | +1186.7% | 7,728 | +1664.4% | 0.00% | +100.0% |
Q2 2020 | $15,000 | – | 438 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Memorial Sloan Kettering Cancer Center | 602,272 | $4,673,631 | 14.75% |
Nextech Invest Ltd. | 4,285,714 | $33,257,141 | 11.30% |
Column Group LLC | 3,568,181 | $27,689,085 | 10.75% |
Prosight Management, LP | 5,522,936 | $42,857,984 | 6.42% |
Invus Financial Advisors, LLC | 1,007,575 | $7,818,782 | 4.18% |
SILVERARC CAPITAL MANAGEMENT, LLC | 1,450,822 | $11,258,379 | 3.48% |
VR Adviser, LLC | 2,142,856 | $16,628,563 | 2.66% |
Euclidean Capital LLC | 747,550 | $5,800,988 | 1.49% |
Frazier Life Sciences Management, L.P. | 2,142,855 | $16,628,555 | 0.99% |
Monaco Asset Management SAM | 378,222 | $2,935,003 | 0.82% |